Clinical and immunogenetic correlates of abacavir hypersensitivity
- 10 June 2005
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in AIDS
- Vol. 19 (9), 979-981
- https://doi.org/10.1097/01.aids.0000171414.99409.fb
Abstract
A patch test (PT) may be useful in defining true abacavir hypersensitivity syndrome (AHS). Seven previously PT-positive patients remote from the original AHS were shown to have robust 24 h responses, supporting PT durability. HLA-B*5701 was present in all seven PT-positive versus one of 11 controls tolerating abacavir (P PKeywords
This publication has 9 references indexed in Scilit:
- Predisposition to abacavir hypersensitivity conferred byHLA-B*5701and a haplotypicHsp70-HomvariantProceedings of the National Academy of Sciences, 2004
- Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populationsPharmacogenomics, 2004
- Epidemiological risk factors for hypersensitivity reactions to abacavir*HIV Medicine, 2003
- Common HLA‐B8‐DR3 haplotype in Northern India is different from that found in EuropeTissue Antigens, 2002
- Utility of patch testing in patients with hypersensitivity syndromes associated with abacavirAIDS, 2002
- HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressorsNature Immunology, 2002
- Association between presence of HLA-B*5701, HLA-DR7 , and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavirThe Lancet, 2002
- Genetic variations in HLA-B region and hypersensitivity reactions to abacavirThe Lancet, 2002
- Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavirClinical Therapeutics, 2001